Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pregnancies diagnosed during Depo-Provera use.

Lynn Borgatta1, Amitasrigowri Murthy, Cynthia Chuang

  • 1Boston University School of Medicine, Department of Obstetrics and Gynecology, Boston, MA, USA. lynn.Borgatta@bmc.org

Contraception
|October 18, 2002
PubMed
Summary

Pregnancy while using Depo-Provera (depot medroxyprogesterone acetate) is rare, occurring in about 0.42 per 1000 women annually. Many pregnancies are unrecognized until after the first trimester.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neural Representation Learning for Compact and Efficient Modeling of Monte Carlo Phase Space Data.

International journal of particle therapy·2026
Same author

A WEb-Accessible comprehensiVE platform for automatic vestibular schwannoma segmentation and longitudinal volumetric tracking.

Neuro-oncology advances·2026
Same author

Vertebral fracture following primary stereotactic body radiation therapy for spinal bone metastases: a decade of experience.

Journal of neurosurgery. Spine·2025
Same author

Primary Stereotactic Body Radiation Therapy for Breast Cancer Spinal Metastases.

Clinical breast cancer·2025
Same author

Use of Carbon Fiber Implants to Improve the Safety and Efficacy of Radiation Therapy for Spine Tumor Patients.

Brain sciences·2025
Same author

Single- versus multi-fraction spine stereotactic radiosurgery (ALL-STAR) for patients with spinal metastases: a randomized phase III trial protocol.

BMC cancer·2025

Area of Science:

  • Reproductive Health
  • Contraception
  • Pharmacovigilance

Background:

  • Depo-Provera (depot medroxyprogesterone acetate) is a widely used injectable contraceptive.
  • Understanding contraceptive failure rates is crucial for effective family planning.
  • Monitoring adverse events and unintended pregnancies is essential for patient safety.

Purpose of the Study:

  • To review contraceptive failures among women using Depo-Provera.
  • To determine the rate of reported pregnancies associated with Depo-Provera use.
  • To analyze the timing of pregnancy diagnosis and management in Depo-Provera users.

Main Methods:

  • Retrospective review of case reports submitted to Planned Parenthood Federation of America's Insurance Division.
  • Inclusion criteria: Depo-Provera administered at a Planned Parenthood center, with pregnancy diagnosed or reported to a Planned Parenthood center.

Related Experiment Videos

  • Data collected from 1994 through 1998, encompassing 402 reported pregnancies.

    • Main Results:

    • A crude pregnancy rate of 0.42 per 1000 women-years was observed.
    • In 46% of cases, pregnancy was diagnosed after the first trimester.
    • Of women with estimated conception dates, 45% became pregnant after their Depo-Provera injection; 19.1% received further injections while pregnant.
    • No increased ectopic pregnancy rate or reported fetal anomalies were noted.

    Conclusions:

    • Pregnancy during Depo-Provera use, while rare, does occur.
    • Delayed recognition of pregnancy is common, often extending beyond the first trimester.
    • Current data suggest no increased risk of ectopic pregnancy or fetal anomalies with Depo-Provera failure.